Methodological Quality of Systematic Reviews on Treatments for Liver Cancer: A Cross-sectional Study.

IF 3.4 3区 医学 Q2 ONCOLOGY
Journal of Hepatocellular Carcinoma Pub Date : 2025-09-16 eCollection Date: 2025-01-01 DOI:10.2147/JHC.S536964
Billy Z Z Cheng, Betty H Wang, Claire Chenwen Zhong, Yuning Zhang, Fai Fai Ho, Vincent C H Chung
{"title":"Methodological Quality of Systematic Reviews on Treatments for Liver Cancer: A Cross-sectional Study.","authors":"Billy Z Z Cheng, Betty H Wang, Claire Chenwen Zhong, Yuning Zhang, Fai Fai Ho, Vincent C H Chung","doi":"10.2147/JHC.S536964","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Systematic reviews (SRs) are indispensable for presenting reliable evidence of the effectiveness of treatments. However, methodological flaws can affect their reliability and validity.</p><p><strong>Aim: </strong>This cross-sectional study aimed to evaluate the methodological quality of SRs on liver cancer (LC) treatments and identify potential factors affecting their reliability.</p><p><strong>Methods: </strong>A comprehensive literature search was carried out on four databases to identify eligible SRs published between January 2014 and October 2023. We appraised the methodological quality of included SRs by Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR 2) tool. Multivariable regression analysis was employed to investigate the factors influencing the methodological quality.</p><p><strong>Results: </strong>A total of 119 SRs were included and appraised. Only one SR (0.8%) was rated as high overall quality. One (0.8%), nine (7.6%), and 108 (90.8%) were appraised as moderate, low, and critical low quality, respectively. SRs published more recently, with higher journal impact factors, or with corresponding author from Europe have better performance.</p><p><strong>Conclusion: </strong>The methodological quality of SRs on LC treatments was unsatisfactory. Future SR authors should improve quality of SRs through registering an a priori protocol, providing explanation for selection of study designs, using a comprehensive literature search strategy, listing all excluded studies and justifying their reasons, describing the included studies in adequate detail, and reporting funding resources of primary studies.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"2109-2121"},"PeriodicalIF":3.4000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450053/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatocellular Carcinoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JHC.S536964","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Systematic reviews (SRs) are indispensable for presenting reliable evidence of the effectiveness of treatments. However, methodological flaws can affect their reliability and validity.

Aim: This cross-sectional study aimed to evaluate the methodological quality of SRs on liver cancer (LC) treatments and identify potential factors affecting their reliability.

Methods: A comprehensive literature search was carried out on four databases to identify eligible SRs published between January 2014 and October 2023. We appraised the methodological quality of included SRs by Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR 2) tool. Multivariable regression analysis was employed to investigate the factors influencing the methodological quality.

Results: A total of 119 SRs were included and appraised. Only one SR (0.8%) was rated as high overall quality. One (0.8%), nine (7.6%), and 108 (90.8%) were appraised as moderate, low, and critical low quality, respectively. SRs published more recently, with higher journal impact factors, or with corresponding author from Europe have better performance.

Conclusion: The methodological quality of SRs on LC treatments was unsatisfactory. Future SR authors should improve quality of SRs through registering an a priori protocol, providing explanation for selection of study designs, using a comprehensive literature search strategy, listing all excluded studies and justifying their reasons, describing the included studies in adequate detail, and reporting funding resources of primary studies.

Abstract Image

肝癌治疗系统评价的方法学质量:一项横断面研究。
背景:系统评价(SRs)是提供治疗有效性可靠证据不可或缺的。然而,方法上的缺陷会影响它们的可靠性和有效性。目的:本横断面研究旨在评估肝癌(LC)治疗中SRs的方法学质量,并确定影响其可靠性的潜在因素。方法:对2014年1月至2023年10月间发表的符合标准的SRs进行综合文献检索。我们通过评估系统评价2的方法学质量(AMSTAR 2)工具评估纳入的SRs的方法学质量。采用多变量回归分析探讨影响方法学质量的因素。结果:共纳入并评价了119例SRs。只有一个SR(0.8%)被评为整体质量高。1件(0.8%)、9件(7.6%)和108件(90.8%)分别被评为中度、低质量和严重低质量。发表时间越近、期刊影响因子越高或通讯作者来自欧洲的论文表现越好。结论:SRs对LC治疗的方法学质量不理想。未来的SR作者应该通过注册一个先验的方案来提高SR的质量,为研究设计的选择提供解释,使用全面的文献检索策略,列出所有被排除的研究并证明其原因,充分详细地描述被纳入的研究,并报告主要研究的资金来源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.50
自引率
2.40%
发文量
108
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信